PM-1022 |
PM-1022 |
Phase 1 Clinical |
Biotheus Inc |
Neoplasms |
Details
|
BAT-6005 |
BAT-6005 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours |
Details
|
ZG-005 |
ZG-005 |
Phase 2 Clinical |
Suzhou Zelgen Biopharmaceuticals Co Ltd |
Solid tumours |
Details
|
SHS-006(Nanjing Sanhome Pharmaceutical) |
SHS-006; SH-006; SH006 |
Phase 1 Clinical |
Nanjing Sanhome Pharmaceutical Co Ltd |
Solid tumours |
Details
|
BAT-6021 |
BAT6021; BAT-6021 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours |
Details
|
DW-2008 |
DW-2008; DW-2008S |
Phase 1 Clinical |
Dong Wha Pharm Co Ltd |
Coronavirus Disease 2019 (COVID-19); Rhinitis, Allergic; Asthma |
Details
|
HB0030 |
HB-0030 |
Phase 1 Clinical |
Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
HH-101 |
HH-101 |
Phase 1 Clinical |
Huahui Health Ltd |
Solid tumours |
Details
|
SEA-TGT |
SGN-TGT; SEA-TGT; SGN-TIGIT |
Phase 1 Clinical |
Seattle Genetics Inc |
Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Skin Melanoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
SHR-2002 |
SHR-2002 |
Phase 1 Clinical |
Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd |
Neoplasms |
Details
|
M-6223 |
M-6223 |
Phase 1 Clinical |
Emd Serono Inc, Merck Serono |
Solid tumours |
Details
|
JS-006 |
JS-006; TAB-006; CHS-006 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Solid tumours; Neoplasms |
Details
|
Domvanalimab |
AB-154 |
Phase 3 Clinical |
Arcus Biosciences Inc, Gilead Sciences Inc |
Solid tumours; Glioblastoma; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms |
Details
|
AZD-2936 |
AZD-2936 |
Phase 2 Clinical |
Astrazeneca Plc |
Carcinoma, Non-Small-Cell Lung |
Details
|
HB-0036 |
HB-0036 |
Phase 2 Clinical |
Huabo Biopharm Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
BC008-1A |
BC008-1A |
Phase 1 Clinical |
Sichuan Luzhou Buchang Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
PM-1021 |
PM1021 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours; Neoplasms |
Details
|
HLX-53 |
HLX-53 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Lymphoma |
Details
|
Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma) |
LP-010 |
Phase 1 Clinical |
Lepu Biotech Co Ltd |
Solid tumours |
Details
|
HLX-301 |
HLX-301 |
Phase 2 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
AK-127 |
AK-127 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
ASP-8374 |
ASP-8374; PTZ-201 |
Phase 1 Clinical |
Potenza Therapeutics, Astellas Pharma Inc |
Solid tumours; Neoplasms; Glioblastoma |
Details
|
Tamgiblimab |
IBI-939 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Neoplasms; Lung Neoplasms |
Details
|
PM-1009 |
PM1009 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours; Neoplasms; Lung Neoplasms |
Details
|
HL-301 |
HL-301 |
Phase 2 Clinical |
Hanlim Pharm Co Ltd |
Radiation Pneumonitis; Lung Neoplasms |
Details
|
Belrestotug |
EOS-448; EOS-884448; GSK-4428859; GSK-4428859A |
Phase 2 Clinical |
Iteos |
Head and Neck Neoplasms; Neoplasms; Multiple Myeloma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
AK-130 |
AK-130 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Neoplasms |
Details
|
AGEN-1777 |
AGEN-1777; BMS-986442 |
Phase 2 Clinical |
Agenus Inc |
Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BMS-986207 |
BMS-986207 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Vibostolimab |
MK-7684 |
Phase 3 Clinical |
Merck Sharp & Dohme Corp |
Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Pembrolizumab/Vibostolimab |
MK-7684A |
Phase 3 Clinical |
Merck & Co Inc |
Ovarian Neoplasms; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms |
Details
|
Tiragolumab |
RG-6058; MTIG-7192A; RO-7092284 |
Phase 3 Clinical |
F. Hoffmann-La Roche Ltd |
Carcinoma, Transitional Cell; Hemangioendothelioma, Epithelioid; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Sarcoma; Lymphoma, Follicular; Multiple Myeloma; Carcinoma, Medullary; Chordoma; Liver Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Rhabdoid Tumor; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Solid tumours; Teratoma |
Details
|
Ociperlimab |
BGB-A1217 |
Phase 3 Clinical |
Beigene Ltd |
Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular |
Details
|
IBI-321 |
IBI-321 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
AB-308 |
AB-308 |
Phase 1 Clinical |
Arcus Biosciences Inc |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
COM-902 |
COM-902 |
Phase 1 Clinical |
Compugen Ltd |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Lung Neoplasms |
Details
|
Etigilimab |
OMP-313M32 |
Phase 2 Clinical |
Oncomed Pharmaceuticals Inc |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|